IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of IGM’s clinical pipeline of proprietary IgM antibodies. He joins IGM with 30 years of experience in cancer research and development, most recently as Senior Vice President, Oncology, Gilead Sciences, Inc. Daniel S. Chen, M.D., Ph.D., will continue to assist the Company in a consulting capacity.
Stanford-university
California
United-states
Texas
Mountain-view
Chrish-takimoto
Daniels-chen
David-pitts
Fred-schwarzer
Translational-medicine-of-ortho-biotech-oncology-research
Us-public-health-service
Yale-university